Statistical Analysis Consultant to Pharmaceutical Companies  

Asking Price:                             $3,500,000

Gross Income:                          $3,600,000

Cash Flow:                                $560,000

EBITDA:                                  $560,000

Business Description

Pharmaceutical Statistical Analysis Consultant

The Company is a statistical consulting firm with clients of pharmaceutical companies, including contract research organizations (CROs). It specializes in supporting statistical data analysis and reporting for clinical and outcome research, and is a key player in assisting pharmaceutical companies throughout the US and internationally win new drug approvals from the FDA.
Experts from the Company analyze clinical trial data and report them per industry standards to assist in winning FDA approvals. When clinical trial raw data becomes available to the Company, usually hundreds of millions of dollars in R&D have already been spent. As a result, it is critical to get this valuable data analyzed and reported with speed and a high degree of accuracy so the high-cost clinical trials can be successfully completed.
The Company operates virtually - employees and contractors operate either from a home office or from a client's location. Its core staff totals 15 full-time employees and 5 to 6 part-time employees (and several additional contractors depending on the workload).

Growth & Expansion:

The Company experienced strong revenue growth over the last three years, increasing an average 16.8% per year. EBITDA consistently increased from 7.4% to 10.3% of sales over the same period. Many of the Company’s key employees and managers have long histories in the industry. This wealth of experience and expertise provides it with a significant intangible value and advantage over many competitors. Revenue for US drug production is forecast to grow at a CAGR of 3% between 2015 and 2019, based on changes in physical volume and unit prices.

Support & Training:

Management is willing to stay with the Company during a transition period in order to ensure a seamless transfer of ownership.

To receive more information Please click here for Non-Disclosure agreemente-mail or fax the executed document to our attention, we will submit the offering upon receipt of your signature, your corporate or personal bio as well as the list of your most recent acquisitions.